Logo image of UPB

UPSTREAM BIO INC (UPB) Stock Fundamental Analysis

USA - NASDAQ:UPB - US91678A1079 - Common Stock

17.57 USD
-0.35 (-1.95%)
Last: 9/12/2025, 8:22:45 PM
17.57 USD
0 (0%)
After Hours: 9/12/2025, 8:22:45 PM
Fundamental Rating

3

Taking everything into account, UPB scores 3 out of 10 in our fundamental rating. UPB was compared to 542 industry peers in the Biotechnology industry. While UPB has a great health rating, there are worries on its profitability. UPB does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year UPB has reported negative net income.
In the past year UPB has reported a negative cash flow from operations.
UPB Yearly Net Income VS EBIT VS OCF VS FCFUPB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -20M -40M -60M

1.2 Ratios

UPB has a Return On Assets of -26.17%. This is in the better half of the industry: UPB outperforms 71.96% of its industry peers.
Looking at the Return On Equity, with a value of -26.93%, UPB is in the better half of the industry, outperforming 79.70% of the companies in the same industry.
Industry RankSector Rank
ROA -26.17%
ROE -26.93%
ROIC N/A
ROA(3y)-59.22%
ROA(5y)N/A
ROE(3y)-136.56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
UPB Yearly ROA, ROE, ROICUPB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for UPB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
UPB Yearly Profit, Operating, Gross MarginsUPB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 -1K -2K -3K

More info and screens

8

2. Health

2.1 Basic Checks

UPB does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for UPB has been increased compared to 1 year ago.
There is no outstanding debt for UPB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
UPB Yearly Shares OutstandingUPB Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M 40M 50M
UPB Yearly Total Debt VS Total AssetsUPB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

UPB has an Altman-Z score of 47.61. This indicates that UPB is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of UPB (47.61) is better than 97.79% of its industry peers.
UPB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 47.61
ROIC/WACCN/A
WACC9.61%
UPB Yearly LT Debt VS Equity VS FCFUPB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 38.27 indicates that UPB has no problem at all paying its short term obligations.
UPB has a better Current ratio (38.27) than 98.71% of its industry peers.
A Quick Ratio of 38.27 indicates that UPB has no problem at all paying its short term obligations.
UPB has a better Quick ratio (38.27) than 98.71% of its industry peers.
Industry RankSector Rank
Current Ratio 38.27
Quick Ratio 38.27
UPB Yearly Current Assets VS Current LiabilitesUPB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 100M 200M 300M 400M

More info and screens

1

3. Growth

3.1 Past

UPB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -99.70%.
The Revenue has decreased by -0.42% in the past year.
EPS 1Y (TTM)-99.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.67%
Revenue 1Y (TTM)-0.42%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-18.52%

3.2 Future

UPB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.34% yearly.
UPB is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -18.90% yearly.
EPS Next Y65.26%
EPS Next 2Y27.64%
EPS Next 3Y18.34%
EPS Next 5YN/A
Revenue Next Year21.55%
Revenue Next 2Y-16.9%
Revenue Next 3Y-18.9%
Revenue Next 5YN/A

3.3 Evolution

UPB Yearly Revenue VS EstimatesUPB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 500K 1M 1.5M 2M 2.5M
UPB Yearly EPS VS EstimatesUPB Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -2 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

UPB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year UPB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
UPB Price Earnings VS Forward Price EarningsUPB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
UPB Per share dataUPB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5

4.3 Compensation for Growth

A more expensive valuation may be justified as UPB's earnings are expected to grow with 18.34% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.64%
EPS Next 3Y18.34%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for UPB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

UPSTREAM BIO INC

NASDAQ:UPB (9/12/2025, 8:22:45 PM)

After market: 17.57 0 (0%)

17.57

-0.35 (-1.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/bmo
Earnings (Next)11-05 2025-11-05
Inst Owners78.74%
Inst Owner Change4.5%
Ins Owners0.05%
Ins Owner Change0%
Market Cap947.20M
Analysts82.5
Price Target76.5 (335.4%)
Short Float %7.86%
Short Ratio6.56
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-11.87%
Min EPS beat(2)-19.62%
Max EPS beat(2)-4.11%
EPS beat(4)0
Avg EPS beat(4)-73.03%
Min EPS beat(4)-181.12%
Max EPS beat(4)-4.11%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)131.66%
Min Revenue beat(2)71.11%
Max Revenue beat(2)192.2%
Revenue beat(4)4
Avg Revenue beat(4)93.28%
Min Revenue beat(4)52.15%
Max Revenue beat(4)192.2%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-12.09%
EPS NY rev (1m)-8.57%
EPS NY rev (3m)-8.57%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)84.29%
Revenue NY rev (1m)54.77%
Revenue NY rev (3m)54.69%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 347.85
P/FCF N/A
P/OCF N/A
P/B 2.32
P/tB 2.32
EV/EBITDA N/A
EPS(TTM)-9.8
EYN/A
EPS(NY)-3
Fwd EYN/A
FCF(TTM)-2.12
FCFYN/A
OCF(TTM)-2.11
OCFYN/A
SpS0.05
BVpS7.58
TBVpS7.58
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -26.17%
ROE -26.93%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-59.22%
ROA(5y)N/A
ROE(3y)-136.56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 377.03%
Cap/Sales 20.49%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 38.27
Quick Ratio 38.27
Altman-Z 47.61
F-Score2
WACC9.61%
ROIC/WACCN/A
Cap/Depr(3y)661.86%
Cap/Depr(5y)N/A
Cap/Sales(3y)11.46%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-99.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.67%
EPS Next Y65.26%
EPS Next 2Y27.64%
EPS Next 3Y18.34%
EPS Next 5YN/A
Revenue 1Y (TTM)-0.42%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-18.52%
Revenue Next Year21.55%
Revenue Next 2Y-16.9%
Revenue Next 3Y-18.9%
Revenue Next 5YN/A
EBIT growth 1Y-93.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-91.2%
EBIT Next 3Y-36.84%
EBIT Next 5YN/A
FCF growth 1Y-56.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-56.02%
OCF growth 3YN/A
OCF growth 5YN/A